Indaptus Therapeutics Announces New Data From Ongoing Phase 1 Trial Of Decoy20; Latest Data From First And Second Cohorts Support Company's 'Pulse-Prime' Approach, Demonstrating Rapid Clearance, Broad Immune Activation, And Encouraging Safety Profile

6/3/24 8:39:45 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $INDP alert in real time by email

Latest data from first and second cohorts support Company's 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile

Poster Presented at American Society of Clinical Oncology Annual Meeting

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced updated data from its ongoing Phase 1 clinical trial of Decoy20 in patients with solid tumors. The data were featured in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1 in Chicago, Illinois.

Get the next $INDP alert in real time by email

Date	Price Target	Rating	Analyst
1/31/2022	$15.00	Buy	HC Wainwright & Co.
10/19/2021	$16.00	Hold → Buy	Maxim Group

Indaptus Therapeutics Announces New Data From Ongoing Phase 1 Trial Of Decoy20; Latest Data From First And Second Cohorts Support Company's 'Pulse-Prime' Approach, Demonstrating Rapid Clearance, Broad Immune Activation, And Encouraging Safety Profile

Chat with this insight

Recent Analyst Ratings for $INDP

$INDP Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

Indaptus Therapeutics To Present At STING & TLR-Targeted Therapies Summit Jun. 19-20

12 Health Care Stocks Moving In Friday's Pre-Market Session

$INDP Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. resumed coverage on Indaptus Therapeutics with a new price target

Indaptus Therapeutics upgraded by Maxim Group with a new price target

$INDP Press Releases

Fastest customizable press release news feed in the world

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

$INDP Financials

Live finance-specific insights

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

$INDP Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by Indaptus Therapeutics Inc.

SEC Form SC 13G/A filed by Indaptus Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Indaptus Therapeutics Inc. (Amendment)

$INDP Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by CEO and Director Meckler Jeffrey A

SEC Form 4 filed by Chief Operating Officer Linscott Walt Addison

SEC Form 4 filed by CSO and Director Newman Michael James

$INDP SEC Filings

Indaptus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Indaptus Therapeutics Inc. filed SEC Form 8-K: Other Events

Amendment: SEC Form D/A filed by Indaptus Therapeutics Inc.

$INDP Leadership Updates

Live Leadership Updates

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Recent Analyst Ratings for
$INDP

$INDP
Market Insights

$INDP
Analyst Ratings

$INDP
Press Releases

$INDP
Financials

$INDP
Large Ownership Changes

$INDP
Insider Trading

$INDP
SEC Filings

$INDP
Leadership Updates